Eric Wieder
Overview
Explore the profile of Eric Wieder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bianchi A, De Castro Silva I, Deshpande N, Singh S, Mehra S, Garrido V, et al.
Cancer Discov
. 2023 Mar;
13(6):1428-1453.
PMID: 36946782
Significance: By decoding connections between high-risk tumor genotypes, cell-autonomous inflammatory programs, and myeloid-enriched/T cell-excluded contexts, we identify a novel role for neutrophil-derived TNF in sustaining immunosuppression and stromal inflammation in...
2.
Florou V, Rosenberg A, Wieder E, Komanduri K, Kolonias D, Uduman M, et al.
J Immunother Cancer
. 2019 Nov;
7(1):285.
PMID: 31694703
Following publication of the original article [1], the authors have reported that the following sentence "While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have...
3.
Florou V, Rosenberg A, Wieder E, Komanduri K, Kolonias D, Uduman M, et al.
J Immunother Cancer
. 2019 Aug;
7(1):213.
PMID: 31395100
Background: Angiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative nature, successful management of localized angiosarcoma is often challenging. Systemic chemotherapy is...
4.
Camargo J, Kimble E, Rosa R, Shimose L, Bueno M, Jeyakumar N, et al.
Biol Blood Marrow Transplant
. 2017 Dec;
24(4):806-814.
PMID: 29217388
The optimal viral load threshold at which to initiate preemptive cytomegalovirus (CMV) therapy in hematopoietic cell transplantation (HCT) recipients remains to be defined. In an effort to address this question,...
5.
Diaz-Montero C, Zidan A, Pallin M, Anagnostopoulos V, Salem M, Wieder E, et al.
Immunol Res
. 2013 Nov;
57(1-3):23-33.
PMID: 24218360
CD62L governs the circulation of CD8(+) T cells between lymph nodes and peripheral tissues, whereby the expression of CD62L by CD8(+) T cells promotes their recirculation through lymph nodes. As...
6.
Diaz-Montero C, Naga O, Zidan A, Salem M, Pallin M, Parmigiani A, et al.
Am J Cancer Res
. 2011 Sep;
1(7):882-96.
PMID: 21915391
Adoptive T-cell therapy holds great promise for the treatment of metastatic melanoma. However, prohibitive costs associated with current technology required for culture and expansion of tumor-reactive T-cells, the need for...
7.
Bayraktar U, Kim T, Drews-Elger K, Benjamin C, El-Ashry D, Wieder E, et al.
Breast Cancer Res Treat
. 2011 May;
129(2):623-8.
PMID: 21607585
The activation of human epidermal growth factor receptor-2 (HER2) results in the activation of the mitogen-activated protein kinase (MAPK) cascade that may lead to the resistance to anti-estrogen therapy in...
8.
He H, Nehete P, Nehete B, Wieder E, Yang G, Buchl S, et al.
PLoS One
. 2011 May;
6(5):e19607.
PMID: 21602924
In HIV infection there is a paucity of literature about the degree of immune dysfunction to potentially correlate and/or predict disease progression relative to CD4(+) T cells count or viral...
9.
Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, et al.
PLoS One
. 2010 Jul;
5(7):e11770.
PMID: 20668669
Background: Interferon-alpha (IFN) induces complete cytogenetic remission (CCR) in 20-25% CML patients and in a small minority of patients; CCR persists after IFN is stopped. IFN induces CCR in part...
10.
Armistead P, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, et al.
Br J Haematol
. 2010 Jun;
150(6):716-9.
PMID: 20560965
No abstract available.